Attorneys for Mylan Laboratories said the generic drug maker will appeal a ruling barring it from marketing a generic version of Pfizer's popular high blood pressure medication, Norvasc. Pfizer sued Mylan in 2002, claiming Mylan infringed on its patent for Norvasc. Mylan acknowledged infringing on the patent, but said it was invalid because it contained the wrong formula. A trial on the lawsuit was held in November and, on Tuesday, a U.S. District judge ruled in Pfizer's favor.
March 01, 2007 at 12:00 AM
1 minute read
The original version of this story was published on Law.Com
Attorneys for Mylan Laboratories Inc. said the generic drug maker will appeal a ruling barring it from marketing a generic version of Pfizer Inc.’s popular high blood pressure medication, Norvasc.
Pfizer sued Mylan in 2002, claiming Mylan infringed on its patent for Norvasc. Mylan acknowledged infringing on the patent, but said it was invalid because it contained the wrong formula.
Presented by BigVoodoo
This conference aims to help insurers and litigators better manage complex claims and litigation.
Recognizing innovation in the legal technology sector for working on precedent-setting, game-changing projects and initiatives.
Legalweek New York explores Business and Regulatory Trends, Technology and Talent drivers impacting law firms.
McManimon, Scotland & Baumann, LLC is seeking talented and motivated associate attorneys for several positions. Candidates must be admi...
Lower Manhattan firm seeks a litigator with at least 2-4 years of experience in all aspects of commercial litigation (i.e., depositions and ...
A prestigious matrimonial law firm in Garden City is seeking a skilled Associate Attorney with 5 to 7 years of experience in family law. The...
